Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences
Dr Margariti has developed significant expertise in stem cell biology, with particular emphasis on cell reprogramming, chromatin remodelling, cell signalling and endothelial cell biology. She had received her postdoctoral training in the Cardiovascular Division of the BHF Centre of Excellence at King’s College London (KCL). Dr Margariti’s laboratory has invested on their robust expertise on cell reprogramming and induced pluripotent stem (iPS) cell technologies and they have developed patient- specific cells lines from diabetic donors (patient specific iPS cell lines in a petri dish) based on fast and highly efficient approaches. Dr Margariti has been promoted to Senior Lecturer in 2017 and she is leading the iPS cells facilities in QUB, where iPS cells are generated and differentiated towards vascular cells (including ECs, Smooth Muscle Cells and Pericytes) and human blood vessel organoids, Cardiomyocyes, Neurons, Retina pigment epithelial cells and many other cell types.
Diabetes has become a major health problem worldwide. Vascular endothelial cell (EC) dysfunction plays a key role in the occurrence of diabetic complications. The current study discovered significant upregulation of Quaking 7 (QKI-7), in induced pluripotent stem (iPS) cell-derived ECs (iPS-ECs) when exposed to hyperglycemia, and in human iPS-ECs from diabetic patients. QKI-7 was also found to be highly expressed in human coronary arterial ECs isolated from diabetic donors, while immunohistochemical staining on blood vessels obtained from diabetic critical limb ischemia patients undergoing a lower limb amputation, QKI-7 expression was detected. QKI-7 expression was found to be tightly controlled by RNA splicing factors CUG-BP and hnRNPM under diabetic conditions. QKI-7 upregulation was correlated with disrupted cell barrier, compromised angiogenesis and enhanced monocyte adhesion in diabetic iPS-ECs. RNA immunoprecipitation (RIP) and mRNA decay assays revealed that QKI-7 bound and promoted mRNA degradation of downstream targets CD144, Neuroligin 1 (NLGN1) and tumor necrosis factor (TNF)-?–stimulated gene/protein 6 (TSG-6). Remarkably, when hindlimb ischemia was induced in diabetic mice and QKI-7 was knockdown in vivo in ECs, reperfusion and blood flow recovery were markedly promoted. Manipulation of QKI-7 represents a novel strategy for the treatment of diabetic vascular complications.